Maurice C. Cox

Maurice C. Cox

Auto-generated profile, based on publicly available information

Maurice C. Cox

Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
SBSven van Den Bosch
Sven van Den Bosch
PDPatricia A.H. Doornaert
Patricia A.H. Doornaert
FHFrank J.P. Hoebers
Frank J.P. Hoebers
BKBas Kreike
Bas Kreike
MVMarije R. Vergeer
Marije R. Vergeer
OSOn Behalf Of The Dutch Head And Neck Society
On Behalf Of The Dutch Head And Neck Society
PURPOSE: Definitive radiotherapy (RT) for head and neck cancer (HNC) has significant long-term toxicity with elective neck irradiation (ENI) as a major contributor. In this multicenter randomized trial, the clinical benefit and safety of definitive RT with reduced versus standard elective dose were compared. METHODS: Newly diagnosed patients with cT2-4N0-2M0 HNC were accrued and treated in five Dutch centers (definitive accelerated RT, 68 Gy in 34 fractions in 5.5 weeks). Patients receiving concurrent chemotherapy were not eligible. Dose for ENI was randomly assigned (2:1; dose reduction, 43 Gy, versus control, 50 Gy). The primary outcome was normalcy of diet score at 1 year. The secondary outcome was recurrence in electively irradiated nodes at 2 years in the dose reduction group with the null hypothesis rejected if the upper-bound one-sided 95% CI exceeded 9%. RESULTS: Between 2016 and 2022, 300 patients were randomnly assigned, of whom 295 were evaluable and included in analysis (dose reduction, 196 and control, 99). The mean normalcy of diet score at 1 year was 91.6 (95% CI, 88.5 to 94.7) in the dose reduction group and 92.6 (95% CI, 88.2 to 97.1) in the control group (mean difference, –1.1 [95% CI, –6.5 to 4.4]). The 2-year recurrence rate in electively irradiated nodes in the dose reduction group was 4.9% (upper-bound one-sided 95% CI, 7.5%). In the control group, this was 4.3% (upper bound one-sided 95% CI, 7.7%). Exploratory analyses demonstrated less acute dysphagia grade ≥3 and better xerostomia-related quality of life in the dose reduction group. CONCLUSION: This is the second randomized controlled trial demonstrating that reduced elective dose is safe in definitive RT for HNC.

5 October 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
SBSven van Den Bosch
Sven van Den Bosch
MCMaurice C. Cox
Maurice C. Cox
PDPatricia A.H. Doornaert
Patricia A.H. Doornaert
FHFrank Hoebers
Frank Hoebers
BKBas Kreike
Bas Kreike
JKJohannes H.A.M. Kaanders
Johannes H.A.M. Kaanders
The multicenter, randomized UPGRADE-RT trial (NCT02442375) evaluated the safety and clinical benefit of elective neck radiotherapy with reduced versus standard dose in head and neck squamous cell carcinoma (SCC). This is a secondary analysis of acute toxicity. Three hundred patients with cT2-4 N0-2 M0 SCC of the oropharynx, larynx or hypopharynx received definitive accelerated radiotherapy alone (34 fractions of 2 Gy in 5.5 weeks). Dose for elective neck irradiation was randomly assigned (ratio 2:1 to dose reduction, 43 Gy versus control, 50 Gy). Radiation induced acute toxicity was scored according to the CTC v2.0 until 90 days after start of radiotherapy. The analysis included 295 evaluable patients (dose reduction, 196 and control, 99). Dysphagia grade ≥ 3 (requiring tube feeding) occurred significantly less in the dose reduction group compared to controls (RR, 0.56, [95 % CI, 0.32 to 0.98], p = 0.046). A mean dose ≥ 45 Gy to the pharyngeal mucosal epithelium was associated with increased rates of mucositis grade ≥ 3 (RR, 1.41, [95 % CI, 1.17 to 1.70], p < 0.001) and dysphagia grade ≥ 3 requiring tube feeding (RR, 3.61, [95 % CI, 1.72 to 7.57], p < 0.001). Less patients in the dose reduction group had a pharyngeal mucosal epithelium mean dose ≥ 45 Gy (RR, 0.80, [95 % CI, 0.65 to 0.99], p = 0.041). Reduced elective dose resulted in significantly more patients with a pharyngeal mucosal epithelium mean dose below 45 Gy. This was associated with a reduced rate of grade ≥ 3 pharyngeal mucositis and a lower rate of acute dysphagia grade ≥ 3 (requiring tube feeding).

25 October 2023 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
MCMaurice C. Cox
Maurice C. Cox
TJTijn Jurcka
Tijn Jurcka
AAAnne IJ Arens
Anne IJ Arens
MRMaartje C. van Rijk
Maartje C. van Rijk
Johannes KaandersJohannes Kaanders
Johannes Kaanders
SBSven van Den Bosch
Sven van Den Bosch
Background: The EANM Research Ltd. (EARL) guidelines give recommendations for harmonization of [18F]FDG PET-CT image acquisition and reconstruction, aiming to ensure reproducibility of quantitative data between PET scanners. Recent technological advancements in PET-CT imaging resulted in an updated version of the EARL guidelines (EARL2). The aim of this study is to compare quantitative [18F]FDG uptake metrics of the primary tumor and lymph nodes in patients with head and neck squamous cell carcinoma (HNSCC) on EARL2 versus EARL1 reconstructed images and to describe clinical implications for nodal staging and treatment. Methods: Forty-nine consecutive patients with HNSCC were included. For all, both EARL1 and EARL2 images were reconstructed from a singular [18F]FDG PET-CT scan. Primary tumors and non-necrotic lymph nodes ≥ 5 mm were delineated on CT-scan. In the quantitative analysis, maximum standardized uptake values (SUVmax) and standardized uptake ratios (SURmax, i.e., SUVmax normalized to cervical spinal cord uptake) were calculated for all lesions on EARL1 and EARL2 reconstructions. Metabolic tumor volume (MTV) and total lesion glycolysis were compared between EARL1 and EARL2 using different segmentation methods (adaptive threshold; SUV2.5/3.5/4.5; SUR2.5/3.5/4.5; MAX40%/50%). In the qualitative analysis, each lymph node was scored independently by two nuclear medicine physicians on both EARL1 and EARL2 images on different occasions using a 4-point scale. Results: There was a significant increase in SUVmax (16.5%) and SURmax (9.6%) of primary tumor and lymph nodes on EARL2 versus EARL1 imaging (p < 0.001). The proportional difference of both SUVmax and SURmax between EARL2 and EARL1 decreased with increasing tumor volume (p < 0.001). Absolute differences in MTVs between both reconstructions were small (< 1.0 cm3), independent of the segmentation method. MTVs decreased on EARL2 using relative threshold methods (adaptive threshold; MAX40%/50%) and increased using static SUV or SUR thresholds. With visual scoring of lymph nodes 38% (11/29) of nodes with score 2 on EARL1 were upstaged to score 3 on EARL2, which resulted in an alteration of nodal stage in 18% (6/33) of the patients. Conclusions: Using the EARL2 method for PET image reconstruction resulted in higher SUVmax and SURmax compared to EARL1, with nodal upstaging in a significant number of patients.

22 August 2021 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
MCMaurice C. Cox
Maurice C. Cox
PBPètra M. Braam
Pètra M. Braam
HRHeidi Rutten
Heidi Rutten
RLRuud van Leeuwen
Ruud van Leeuwen
MWMarkus Wendling
Markus Wendling
In rectal cancer patients, radiotherapy in prone position using a belly board can reduce the dose to organs at risk. For this patient group we investigated inter-fraction shape variation of the mesorectal part of the clinical target volume (CTV) and determined planning target volume (PTV) margins. Patients with rectal cancer receiving neoadjuvant (chemo)radiotherapy were eligible. For each patient a planning computed tomography (pCT) and five cone-beam CT (CBCT) scans were acquired in prone position using a belly board. The mesorectal CTV was delineated on all scans. Mesorectal shape variation was quantified relative to the pCT. PTV margins were derived locally and averaged for separate subregions of the mesorectal CTV. For each patient a total PTV was constructed using our clinical margins for mesorectal and lymph node CTVs. An artificial dose distribution conforming to this PTV was used to calculate the coverage for the mesorectal CTV using the CBCT delineations. In 19 rectal cancer patients the derived PTV margins were smallest in the upper-lateral region (6 mm) and largest in the upper-anterior region (16 mm). PTV margins for the upper-anterior region were larger for female patients (19 mm) compared to male patients (14 mm). Clinical margins for the total PTV were sufficient for a coverage of at least 97% of the mesorectal CTV for all patients. Mesorectal shape variation is heterogeneous and largest in the upper-anterior region, in rectal cancer patients irradiated in prone position and using a belly board.

1 January 2021 in Journal of Cancer Metastasis and Treatment
Verified
Journal Article
Open access
PDF file
MCMaurice C. Cox
Maurice C. Cox
SBSven van Den Bosch
Sven van Den Bosch
TDTim Dijkema
Tim Dijkema
JKJohannes H.A.M. Kaanders
Johannes H.A.M. Kaanders
Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic and clinical studies related to cancer cell, cell biology, oncology, radiation therapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neuro-oncology, etc.

20 April 2023 in Research Square
Verified
Preprint
Open access
PDF file
MCMaurice C. Cox
Maurice C. Cox
TJTijn Jurcka
Tijn Jurcka
AAAnne I.J. Arens
Anne I.J. Arens
MRMaartje C. van Rijk
Maartje C. van Rijk
JKJohannes H.A.M. Kaanders
Johannes H.A.M. Kaanders
SBSven van Den Bosch
Sven van Den Bosch
Background: The EANM Research Ltd. (EARL) guidelines give recommendations for harmonization of [18F]FDG PET-CT image acquisition and reconstruction, aiming to ensure reproducibility of quantitative data between PET scanners. Recent technological advancements in PET-CT imaging resulted in an updated version of the EARL guidelines (EARL2). The aim of this study is to compare quantitative [18F]FDG uptake metrics of the primary tumor and lymph nodes in patients with head and neck squamous cell carcinoma (HNSCC) on EARL2 versus EARL1 reconstructed images and to describe clinical implications for nodal staging and treatment.Methods: Forty-nine consecutive patients with HNSCC were included. For all, both EARL1 and EARL2 images were reconstructed from a singular [18F]FDG PET-CT scan. Primary tumors and non-necrotic lymph nodes ≥ 5mm were delineated on CT-scan. In the quantitative analysis, maximum standardized uptake values (SUVmax) and standardized uptake ratios (SURmax, i.e. SUVmax normalized to cervical spinal cord uptake) were calculated for all lesions on EARL1 and EARL2 reconstructions. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were compared between EARL1 and EARL2 using different segmentation methods (adaptive threshold; SUV2.5/3.5/4.5; SUR2.5/3.5/4.5; MAX40%/50%). In the qualitative analysis, each lymph node was scored independently by two nuclear medicine physicians on both EARL1 and EARL2 images on different occasions using a 4-point scale.Results: There was a significant increase of SUVmax (19%) and SURmax (11%) of primary tumor and lymph nodes on EARL2 versus EARL1 imaging (p < 0.001). The proportional difference of both SUVmax and SURmax between EARL2 and EARL1 decreased with increasing tumor volume (p < 0.001). Absolute differences in MTVs between both reconstructions were small (< 1.0cm3), independent of the segmentation method. Relative differences in MTVs and TLGs were small using the adaptive threshold method and larger using static SUV or SUR thresholds. With visual scoring of lymph nodes 38% (11/29) of nodes with score 2 on EARL1 were upstaged to score 3 on EARL2, which resulted in an alteration of nodal stage in 18% (6/33) of the patients.Conclusions: Using the EARL2 method for PET image reconstruction resulted in higher SUVmax and SURmax compared to EARL1, with nodal upstaging in a significant number of patients.